Guido Oelkers wird spätestens zum 1. Februar neuer Vorstandsvorsitzender von Biontech und tritt damit die Nachfolge von Mitbegründer Ugur Sahin an. Er soll vor allem das wichtige US-Geschäft des Mainzer Biopharma-Unternehmens ankurbeln.
China's NMPA has approved a rare-disease therapy for commercial sales to treat narcolepsy type 1 in individuals aged 16 and older. The unnamed drug previously received fast-track status in the US and orphan-drug designation in Japan and the EU, indicating international recognition for its importance.
South Korea's biopharmaceutical exports are projected to reach a record high in the first half of this year, with an estimated $4.5 billion in shipments, a 15.3% increase. The sector's growth is driven by recombinant protein drugs, with key export markets including Switzerland, the United States, and Hungary.
South Korea's biopharmaceutical exports reached a record $4.5 billion in the first half of 2024, a 15.3% increase year-on-year. This surge represents 86.5% of total pharmaceutical exports, with significant growth in US and European markets. Projections indicate a new annual record if the upward trend continues.
Royalty Pharma, the world's largest biopharmaceutical royalty buyer, established its first Asia-Pacific base in Hong Kong. This move aims to capitalize on record Chinese biotech out-licensing deals and offers an alternative financing method amidst US investment restrictions and geopolitical uncertainties.
Ukrainian pharmaceutical companies are reportedly exiting the country due to a severe shortage of specialists and labor. Biopharma plans to open an €85 million production facility in Romania by late 2027.
The IPO window for biotech companies is open, but strong firms may still opt for M&A with Big Pharma. Investors are selective, favoring 'best in class' assets. Deal values are increasing, with China emerging as a key player.
The biotech IPO market is showing signs of recovery, but top dealmakers at JPMorgan suggest strong companies may still opt for acquisition by Big Pharma. Investors are more selective, leading many biotechs to pursue dual-track strategies. This trend reflects a broader healthcare dealmaking rebound driven by Big Pharma's need to replenish pipelines.
The biotech IPO market is showing signs of life, but top dealmakers at JPMorgan suggest that strong companies are still more likely to be acquired by Big Pharma. Investors are more selective, leading many biotechs to pursue dual-track strategies.
The US Department of Defense added WuXi AppTec to its list of Chinese military companies. Analysts predict minimal impact on the company and the broader pharma sector due to cost efficiencies and ongoing collaboration.
Global biopharma M&A is accelerating in 2026, driven by patent cliffs and pipeline needs. Dealmaking has reached $106 billion, on track to exceed $250 billion, the highest since 2019. Strategic 'bolt-on' acquisitions under $5 billion dominate, with a growing interest in Chinese assets.
SEOUL, May 6 (Yonhap) -- Celltrion Inc., a major South Korean biopharmaceutical ...
Das Biopharma-Unternehmen Biontech schließt Werke, Tausende Jobs sind in Gefahr. Was wie eine Reaktion auf den Einbruch der Impfnachfrage klingt, ist in Wirklichkeit die Quittung für Jahre verschlafener Entscheidungen.
Der Impfstoffhersteller Biontech plant die Schließung mehrerer Produktionsstandorte. Insgesamt bis zu 1860 Stellen könnten von den Einschnitten betroffen sein, kündigt das Biopharma-Unternehmen in Mainz an.
The Constitutional Court of South Korea will hear a complaint from GC Biopharma regarding a fine for bid-rigging, marking the first time the court has accepted such a case under new judicial reform legislation.
Servier a mené «avec succès» son offre publique d’achat visant la totalité des actions de l’entreprise biopharmaceutique américaine Day One Biopharmaceuticals.
Celltrion Inc., a leading South Korean biopharmaceutical company, announced plans to repurchase 100 billion won (US$68 million) worth of its own shares to enhance shareholder value and support the company's valuation amid external uncertainties stemming from Middle East tensions. The company also cancelled treasury shares worth 1.8 trillion won last week under a broader shareholder return initiative.
